Biopharma Stocks: Strong In The Good Times, But Even Better During Bad
Executive Summary
As biotech stocks start to look a bit top-heavy and choppy, how well do biotech and pharma function as “defensive” stocks for investors looking to escape the brutalities of a bear market?
You may also be interested in...
Social Norms Shift, But U.S. Rules On Cannabis-Related Drug R&D Lag Behind
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
New HBV Technologies Start To Take Hold In Quest For A Cure
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.
Deerfield’s Private Designs
Deerfield Management has a blank slate with its new $1.6 billion fund for health care investment, the third that it’s dedicated to private company investment and public company structured financing. The hedge fund is trying to reprise the performance of its prior two Private Design funds, for which it claims only one loss thus far in each.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: